Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11,173 Mln
Revenue (TTM)
$982 Mln
Net Profit (TTM)
$0 Mln
ROE
-45.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
55.7
Industry P/E
--
EV/EBITDA
-5.4
Div. Yield
0 %
Debt to Equity
-16.9
Book Value
$--
EPS
$-3.3
Face value
--
Shares outstanding
131,170,441
CFO
$-1,175.65 Mln
EBITDA
$-2,054.71 Mln
Net Profit
$-2,047.36 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Guardant Health (GH)
| -17.2 | -13.6 | -17.8 | 84.6 | 51.8 | -9.0 | -- |
|
BSE Sensex
| -13.1 | -10.5 | -13.5 | -4.8 | 8.6 | 8.5 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Guardant Health (GH)
| 234.3 | 12.8 | -0.6 | -72.8 | -22.4 | 64.9 | 107.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Guardant Health (GH)
|
84.6 | 11,173.1 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 |
| 57.8 | 7,888.0 | 1,091.0 | 202.3 | 31.6 | 31.3 | 35.2 | 13.9 | |
| 62.5 | 7,599.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 41.5 | 11,065.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.8 | 5.0 | |
| 61.6 | 7,485.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.7 | 153.4 | |
| 7.4 | 8,708.1 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 510.7 | 10,120.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 451.2 | 12,842.8 | 2,530.2 | 451.1 | 21.3 | 70.2 | 29.6 | 28.5 | |
| 96.7 | 7,450.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 290.1 | 8,308.2 | 0.0 | -303.3 | -- | -45.8 | -- | 9.5 |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360... Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California. Read more
Co-Founder, Co-CEO & Chairman
Dr. Helmy Eltoukhy Ph.D.
Co-Founder, Co-CEO & Chairman
Dr. Helmy Eltoukhy Ph.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Guardant Health Inc (GH) is $84.61 (NASDAQ) as of 27-Mar-2026 16:00 EDT. Guardant Health Inc (GH) has given a return of 51.82% in the last 3 years.
Since, TTM earnings of Guardant Health Inc (GH) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-30.67
|
-128.57
|
|
2024
|
-8.61
|
-26.91
|
|
2023
|
-6.32
|
19.09
|
|
2022
|
-4.24
|
46.10
|
|
2021
|
-24.90
|
15.66
|
The 52-week high and low of Guardant Health Inc (GH) are Rs 120.74 and Rs 36.36 as of 28-Mar-2026.
Guardant Health Inc (GH) has a market capitalisation of $ 11,173 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Guardant Health Inc (GH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-3.49
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.